logo image
search icon
RNAi Drug Delivery Market

RNAi Drug Delivery Market Size, Share & Trends Analysis By Target Disease ( Cancer, Metabolic Diseases, Genetic Disorders, Viral Infections, Others), By Technology (miRNA, siRNA, shRNA, Others), By Targeted Tissue (Heart, Brain, Liver, Lungs, Others), By Delivery System (Nanoparticle Drug Delivery Technology, Aptamer Drug Delivery Technology, Pulmonary Drug Delivery Technology, Nucleic Acid Drug Delivery Technology), By Route of Administration (Oral, Intramuscular, Intravenous, Local Injection, Subcutaneous), By End-User), by Region, And by Segment Forecasts, 2025-2034

Report ID : 3095 | Published : 2025-06-19 | Pages: 179 | Format: PDF/EXCEL/Power BI Dashbord

RNAi Drug Delivery Market Size is valued at USD 108.8 Bn in 2024 and is predicted to reach USD 559.6 Bn by the year 2034 at a 18.1% CAGR during the forecast period for 2025-2034.

RNAi Drug Delivery Market info

Drug delivery using RNA interference (RNAi) holds promise for the creation of new treatments, especially in the field of gene expression modification. This strategy uses RNA interference (RNAi), a natural mechanism, to silence particular genes, potentially providing therapies for a variety of illnesses. To introduce therapeutic nucleic acids into cells, RNAi drug delivery systems use various techniques. Among these are topical, pulmonary, intravenous, intradermal, and intraperitoneal administration. Synthetic delivery vehicles such as nanoparticles, nanocarriers, and vectors are frequently used to improve the stability and effectiveness of RNA interference treatments.

The global RNAi drug delivery market is mostly driven by the rising incidence of diseases, including cancer and cardiovascular disorders, as well as creative uses of drug delivery technology. When compared to protein and small-molecule medications, for example, aptamer drug delivery technology has a number of advantages, including a lower chance of human side effects and difficulties, as well as improved drug-like qualities, including stability and bloodstream residence length. The worldwide RNAi drug delivery market has also expanded due to increased research in the field of RNA therapies.

However, some of the main obstacles to the worldwide RNAi drug delivery industry include high investment costs and strict regulations. Furthermore, a major obstacle facing the worldwide RNAi drug delivery industry is the targeted distribution of RNA molecules. Many businesses working on RNA treatments are having trouble getting RNA molecules to target tissues in a way that will have a therapeutic impact. Nonetheless, more research in the realm of nanotechnology creates opportunities for the global market for RNAi drug delivery.

Competitive Landscape

Some Major Key Players In The RNAi Drug Delivery Market:

  • Pfizer
  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Ionis Pharmaceuticals
  • Moderna Therapeutics
  • Sanofi
  • Takeda Pharmaceutical
  • Arcturus Therapeutics
  • Bayer
  • BioNTech
  • Roche
  • Regeneron Pharmaceuticals
  • Viridian Therapeutics
  • Other Market Players

Market Segmentation:

The RNAi Drug Delivery market is segmented based on target disease, technology, targeted tissue, delivery system, route of administration, and end-user. Based on target disease, the market is segmented into Cancer, Metabolic Diseases, Genetic Disorders, Viral Infections, and Others. By technology, the market is segmented into miRNA, siRNA, shRNA, and Others. By targeted tissue, the market is segmented into Heart, Brain, Liver, Lungs, and Others. By delivery system, the market is segmented into Nanoparticle Drug Delivery Technology, Aptamer Drug Delivery Technology, Pulmonary Drug Delivery Technology, and Nucleic Acid Drug Delivery Technology. By route of administration, the market consists of Oral, Intramuscular, Intravenous, Local Injection, and Subcutaneous. By end-user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Government and Regulatory Bodies, and Contract Research Organizations (CROs).

Based On The Technology, The Sirna Segment Is Accounted As A Major Contributor To The RNAi Drug Delivery Market.

The siRNA category is expected to hold a major global market share in 2024 because of its growing use in gene-silencing treatments for a variety of illnesses, especially viral infections, malignancies, and genetic disorders. siRNA molecules are a viable therapeutic alternative because of their great specificity and potency in silencing genes that cause disease. Investment in this field has been stimulated by the approval of siRNA-based medications like patisiran and givosiran, which further prove the clinical potential of siRNA. The development and commercialization of siRNA therapies are progressing more quickly due to technological developments in delivery systems, particularly lipid nanoparticles and conjugate-based techniques, which are overcoming earlier obstacles relating to stability, off-target effects, and cellular uptake.

Nanoparticle Drug Delivery Technology Segment To Witness Growth At A Rapid Rate

A major development in healthcare is represented by nanoparticle drug delivery systems, which use materials at the nanoscale for targeted, controlled drug delivery and diagnostic purposes. These systems use nanotechnology to accurately deliver treatments to targeted areas, providing clear benefits in the treatment of chronic illnesses. It is noteworthy that RNAi therapies have become popular in the treatment of many diseases because of the special characteristics of nanoparticles, namely their size. Chemotherapeutics, biological agents, and immunotherapeutics are among the medications that fall under the category of nanoparticle-mediated therapies. Additionally, effective RNAi drug delivery is made possible by technological developments in synthetic delivery carriers, such as nanocarriers and bio vectors, which reduce potential immunogenicity and RNase degradation. 

In The Region, The North American RNAi Drug Delivery Market Holds A Significant Revenue Share.

The North American RNAi Drug Delivery market is expected to report the highest market share in revenue in the near future because chronic diseases that need improved RNA-based therapies to treat patients are becoming more common. Drug delivery strategies that are specific to these RNAi-based treatments are needed, including aptamer, pulmonary, and nanoparticle technologies. Furthermore, the need for RNAi drug delivery methods has increased in this area due to the growing body of research on sophisticated RNAi-based treatments.

In addition, Europe is estimated to grow rapidly in the global RNAi Drug Delivery market driven by the expanding customized medicine movement, which urges the use of certain drug delivery techniques to improve the stability & effectiveness of medications at particular sites. The rapid growth of countries is also expected because most of the region's firms have made large investments.

RNAi Drug Delivery Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2024

USD 108.8 Bn

Revenue Forecast In 2034

USD 559.6 Bn

Growth Rate CAGR

CAGR of 18.1% from 2025 to 2034

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2025 to 2034

Historic Year

2021 to 2024

Forecast Year

2025-2034

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Target Disease, Technology, Targeted Tissue, Delivery System, Route Of Administration, And End-User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia

Competitive Landscape

AbbVie, Alma Lasers, Merz Pharma, Solta Medical, Bausch Health Companies, Candela, Lumenis, Sisram Medical, Cutera, Allergen, Cynosure,Fotona, HTM Eletronica, Johnson & Johnson, and Syneron Candela.

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global RNAi Drug Delivery Market Snapshot

Chapter 4. Global RNAi Drug Delivery Market Variables, Trends & Scope

4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global RNAi Drug Delivery Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on RNAI DRUG DELIVERY MARKET Industry Trends

Chapter 5. RNAi Drug Delivery Market Segmentation 1: By Technology, Estimates & Trend Analysis

5.1. Market Share by Technology, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:

5.2.1. siRNA
5.2.2. miRNA
5.2.3. shRNA
5.2.4. Others

Chapter 6. RNAi Drug Delivery Market Segmentation 2: By Target Disease, Estimates & Trend Analysis

6.1. Market Share by Target Disease, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Target Disease:

6.2.1. Cancer
6.2.2. Viral Infections
6.2.3. Genetic Disorders
6.2.4. Metabolic Diseases
6.2.5. Other Diseases

Chapter 7. RNAi Drug Delivery Market Segmentation 3: By Delivery System, Estimates & Trend Analysis

7.1. Market Share by Delivery System, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery System:

7.2.1. Nanoparticle Drug Delivery Technology
7.2.2. Pulmonary Drug Delivery Technology
7.2.3. Nucleic Acid Drug Delivery Technology
7.2.4. Aptamer Drug Delivery Technology

Chapter 8. RNAi Drug Delivery Market Segmentation 4: By Targeted Tissue, Estimates & Trend Analysis

8.1. Market Share by Targeted Tissue, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Targeted Tissue:

8.2.1. Liver
8.2.2. Lungs
8.2.3. Brain
8.2.4. Heart
8.2.5. Others

Chapter 9. RNAi Drug Delivery Market Segmentation 5: By Route of Administration, Estimates & Trend Analysis

9.1. Market Share by Route of Administration, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:

9.2.1. Intravenous
9.2.2. Intramuscular
9.2.3. Subcutaneous
9.2.4. Local Injection
9.2.5. Oral

Chapter 10. RNAi Drug Delivery Market Segmentation 6: By End User, Estimates & Trend Analysis

10.1. Market Share by End User, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:

10.2.1. Pharmaceutical Companies
10.2.2. Biotechnology Companies
10.2.3. Contract Research Organizations (CROs)
10.2.4. Academic and Research Institutions
10.2.5. Government and Regulatory Bodies

Chapter 11. RNAi Drug Delivery Market Segmentation 7: Regional Estimates & Trend Analysis


11.1. Global RNAi Drug Delivery Market, Regional Snapshot 2024 & 2034

11.2. North America

11.2.1. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.2.1.1. US
11.2.1.2. Canada

11.2.2. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.2.3. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.2.4. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.2.5. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.2.6. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.2.7. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

11.3. Europe

11.3.1. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe

11.3.2. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.3.3. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.3.4. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.3.5. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.3.6. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.3.7. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

11.4. Asia Pacific

11.4.1. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.4.1.1. India
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific

11.4.2. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.4.3. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.4.4. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.4.5. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts By Targeted Tissue, 2021-2034
11.4.6. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.4.7. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

11.5. Latin America

11.5.1. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Latin America

11.5.2. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.5.3. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.5.4. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.5.5. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.5.6. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.5.7. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

11.6. Middle East & Africa

11.6.1. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

11.6.1.1. GCC Countries
11.6.1.2. Israel
11.6.1.3. South Africa
11.6.1.4. Rest of Middle East and Africa

11.6.2. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.6.3. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.6.4. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.6.5. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.6.6. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles

12.2.1. Alnylam Pharmaceuticals
12.2.1.1. Business Overview
12.2.1.2. Key Product/Service
12.2.1.3. Financial Performance
12.2.1.4. Geographical Presence
12.2.1.5. Recent Developments with Business Strategy
12.2.2. Arrowhead Pharmaceuticals
12.2.3. Arcturus Therapeutics
12.2.4. Bayer
12.2.5. BioNTech
12.2.6. Dicerna Pharmaceuticals
12.2.7. Ionis Pharmaceuticals
12.2.8. Moderna Therapeutics
12.2.9. Novartis
12.2.10. Pfizer
12.2.11. Roche
12.2.12. Regeneron Pharmaceuticals
12.2.13. Sanofi
12.2.14. Takeda Pharmaceutical
12.2.15. Viridian Therapeutics

Segmentation of RNAi Drug Delivery Market-

RNAi Drug Delivery Market By Target Disease-

  • Cancer
  • Metabolic Diseases
  • Genetic Disorders
  • Viral Infections
  • Others

RNAi Drug Delivery Market seg

RNAi Drug Delivery Market By Technology-

  • miRNA
  • siRNA
  • shRNA
  • Others

RNAi Drug Delivery Market By Targeted Tissue-

  • Heart
  • Brain
  • Liver
  • Lungs
  • Others

RNAi Drug Delivery Market By Delivery System-

  • Nanoparticle Drug Delivery Technology
  • Aptamer Drug Delivery Technology
  • Pulmonary Drug Delivery Technology
  • Nucleic Acid Drug Delivery Technology

RNAi Drug Delivery Market By Route of Administration-

  • Oral
  • Intramuscular
  • Intravenous
  • Local Injection
  • Subcutaneous

RNAi Drug Delivery Market By End-User-

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutions
  • Government and Regulatory Bodies
  • Contract Research Organizations (CROs)

RNAi Drug Delivery Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the RNAi Drug Delivery Market Size?

RNAi Drug Delivery Market is expected to grow at a 18.1% CAGR during the forecast period for 2025-2034.

AbbVie, Alma Lasers, Merz Pharma, Solta Medical, Bausch Health Companies, Candela, Lumenis, Sisram Medical, Cutera, Allergen, Cynosure,Fotona, HTM Ele

RNAi Drug Delivery market is segmented based on target disease, technology, targeted tissue, delivery system, route of administration, and end-user.

North America region is leading the RNAi Drug Delivery Market.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Report License Selection

Determine the appropriate license for your report

Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach